On Monday, GABA Therapeutics commenced dosing for its phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia. The phase I, two-stage, double-blind, placebo-controlled single and multiple dose study is evaluating the pharmacokinetics, pharmacodynamics, and safety of oral etifoxine in up to 34 normal healthy volunteers.
GABA Therapeutics commences phase I study of Etifoxine
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced…
JOIN THE ATAI #INSIGHTNETWORK